Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
Department of Internal Medicine, White River Health System, Batesville, AR 72501, USA.
Curr Oncol. 2022 Mar 5;29(3):1695-1708. doi: 10.3390/curroncol29030141.
Autophagy has been of novel interest since it was first demonstrated to have effect in Burkitt's lymphoma. Since that time, the autophagy agents chloroquine and hydroxychloroquine have become the only FDA (Food and Drug Administration)-approved autophagy inhibitors. While not approved for cancer therapy, there are ongoing clinical trials to evaluate their safety and efficacy. Pevonedistat has emerged as a novel inhibitor through the neddylation pathway and is an autophagy activator. This paper summarizes and presents current clinical trials for hydroxychloroquine (HCQ), chloroquine (CQ), and Pevonedistat for the clinician.
自自噬首次被证明对伯基特淋巴瘤有影响以来，它一直引起人们的关注。从那时起，自噬剂氯喹和羟氯喹已成为唯一获得美国食品和药物管理局（FDA）批准的自噬抑制剂。虽然它们未被批准用于癌症治疗，但目前正在进行临床试验以评估其安全性和疗效。Pevonedistat 通过泛素化途径成为一种新型抑制剂，也是一种自噬激活剂。本文总结并介绍了目前针对羟氯喹（HCQ）、氯喹（CQ）和 Pevonedistat 的临床试验，以供临床医生参考。
